Your email has been successfully added to our mailing list.

×
0.000424028268551347 -0.00353356890459356 0 0 0.0201413427561839 0.00706713780918729 -0.0247349823321554 -0.0247349823321554
Stock impact report

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach [Yahoo! Finance]

MAIA Biotechnology, Inc. (MAIA) 
Company Research Source: Yahoo! Finance
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class—telomere-targeting agents—is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy. Show less Read more
Impact Snapshot
Event Time:
MAIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MAIA alerts
Opt-in for
MAIA alerts

from News Quantified
Opt-in for
MAIA alerts

from News Quantified